Last reviewed · How we verify

LY2189265 and Lifestyle Measures

Eli Lilly and Company · Phase 2 active Small molecule

LY2189265 and Lifestyle Measures is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 2 development. Also known as: Dulaglutide.

At a glance

Generic nameLY2189265 and Lifestyle Measures
Also known asDulaglutide
SponsorEli Lilly and Company
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LY2189265 and Lifestyle Measures

What is LY2189265 and Lifestyle Measures?

LY2189265 and Lifestyle Measures is a Small molecule drug developed by Eli Lilly and Company.

Who makes LY2189265 and Lifestyle Measures?

LY2189265 and Lifestyle Measures is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is LY2189265 and Lifestyle Measures also known as anything else?

LY2189265 and Lifestyle Measures is also known as Dulaglutide.

What development phase is LY2189265 and Lifestyle Measures in?

LY2189265 and Lifestyle Measures is in Phase 2.

Related